MedPath
HSA Approval

AREXVY Powder and Suspension for Suspension for Injection 120mcg/0.5mL

SIN17008P

AREXVY Powder and Suspension for Suspension for Injection 120mcg/0.5mL

AREXVY Powder and Suspension for Suspension for Injection 120mcg/0.5mL

May 10, 2024

GLAXOSMITHKLINE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGLAXOSMITHKLINE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION

INTRAMUSCULAR

Medical Information

J07BX05

Manufacturer Information

GLAXOSMITHKLINE PTE LTD

GlaxoSmithKline Biologicals SA

GlaxoSmithKline Biologicals SA (adjuvant)

GlaxoSmithKline Vaccines S.r.l. (adjuvant)

Active Ingredients

RSVPreF3 antigen

120mcg/0.5mL

rsvpref 3 antigen

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

AREXVY Powder and Suspension for Suspension for Injection 120mcg/0.5mL - HSA Approval | MedPath